Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006032 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer
A Phase 2 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
NCT00006032: Clinical Trial Phase 2 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
NCT00006032 is a Phase 2 study that was terminated before completion, run by H. Lee Moffitt Cancer Center and Research Institute. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00006032, a Phase 2 study, was terminated before completion, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy followed by autologous peripheral stem cell transplantation in treating women who have metastatic breast cancer.
Interventions
- DRUG etoposide
- DRUG ifosfamide
- PROCEDURE peripheral blood stem cell transplantation
- DRUG topotecan hydrochloride
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-03 |
| Est. Completion | 2001-04 |
| Phase | Phase 2 |
Why NCT00006032 stopped before completion
NCT00006032 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 4 interventions - of which etoposide is the first listed.
NCT00006032 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00006032 about?
NCT00006032 is a clinical study titled "Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase II trial...
What is the current status of trial NCT00006032?
This trial is currently terminated. It is a Phase 2 study. The study started on 2000-03. Estimated completion is 2001-04.
What interventions are being tested in trial NCT00006032?
The interventions under investigation include: etoposide (DRUG), ifosfamide (DRUG), peripheral blood stem cell transplantation (PROCEDURE), topotecan hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00006032?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia